Hangzhou Grand Biologics Pharmaceutical

Hangzhou Grand Biologics Pharmaceutical is a specialized biopharmaceutical company based in China, primarily focused on the research, development, and commercialization of microbial-based therapeutics. A key subsidiary of China Grand Pharmaceutical and Healthcare Holdings, the company is best known for its flagship product, the Bifidobacterium Tetravaccine (Live) (brand name: Siliankang), which is used to treat various gastrointestinal disorders by restoring gut microbiota balance. The company operates large-scale GMP-certified manufacturing facilities for live biotherapeutic products and maintains a strong market presence in the digestive health sector. Beyond its core probiotic portfolio, Hangzhou Grand Biologics is expanding its pipeline into broader biotechnology applications and microbial medicine.